Keflex
PreclinicalSmall molecule
Keflex is one of 14 small molecule programs targeting Antibiotics. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Antibiotics
#DrugCompanyPhaseTrials
1Vancocin
HHikma Pharmaceuticals LLC
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ancef
BBaxter Healthcare Corporation
Approved
Levaquin
WWim Janssens
Approved
Flagyl
DDePuy Orthopaedics
Phase 3
Cipro
BayerPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
Xtandi
AstellasPhase 2
Sulfamethoxazole-Trimethoprim
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Azithromycin Pill
RRambam Health Care Campus
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Keflex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pennsylvania